Detail akcie Bone Bio Rg online

Business Summary: Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Bone Biologics Corp revenues was not reported. Net loss applicable to common stockholders decreased 58% to $2.4M. Lower net loss reflects Bone regeneration segment loss decrease of 6% to $2.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$26.10 to -$3.62.